Could a lung drug stop debilitating nosebleeds?

NCT ID NCT04976036

Recruiting now Disease control Sponsor: Dr. Romain Lazor Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a drug called nintedanib can reduce the frequency and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder. About 48 adult participants with moderate to severe nosebleeds will take either nintedanib or a placebo capsule twice daily for 16 weeks after an initial observation period. The main goal is to see if the drug helps people spend less time bleeding from their nose each month.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TELANGIECTASIA, HEREDITARY HEMORRHAGIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Angiology Department, Lausanne University Hospital
COMPLETED

Lausanne, Canton of Vaud, 1011, Switzerland
Clermont-Ferrand university hospital
RECRUITING

Clermont-Ferrand, 63000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Lyon University Hospital, Dpt of genetics
RECRUITING

Bron, 69677, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TELANGIECTASIA, HEREDITARY HEMORRHAGIC